Abstract
Patients with kidney failure are at increased risk during the COVID-19 pandemic and effective vaccinations are needed. It is not known how efficient mRNA vaccines mount B and plasma cell responses in dialysis patients (DP) or kidney transplant recipients (KTR) compared to healthy controls (HC). We studied humoral and B cell responses of 25 HC, 44 DP and 40 KTR. Markedly impaired anti-BNT162b2 responses were identified among KTR and DP compared to 100% seroconversion in HC. In DP, the response was delayed (3-4 weeks after boost) and reduced with anti-S1 IgG positivity in 31 (70.5%) and anti-S1 IgA in 30 (68.2%) of 44, respectively. In contrast, KTR did not develop IgG response except one patient who had prior unrecognized infection and developed anti-S1 IgG. The majority of antigen-specific B cells (RBD+) were identified in the plasmablast or post-switch memory B cell compartments in HC, whereas these RBD+ B cells were enriched among pre-switch and naïve B cells from DP and KTR. Single cell transcriptome and CITE-seq analyses found reduced frequencies of plasmablasts, TCF7+CD27+GZMK+ T cells and proliferating MKI67-expressing lymphocytes among KTR non-responders. Importantly, the frequency and absolute number of antigen-specific circulating plasmablasts in the whole cohort correlated with the Ig response, a characteristic not reported for other vaccinations. In conclusion, this data indicate that lack of T cell help related to immunosuppression results in impaired germinal center differentiation of B and plasma cell memory. There is an urgent need to improve vaccination protocols in patients after kidney transplantation or on chronic dialysis.
One Sentence Summary Kidney transplant recipients and dialysis patients show a markedly diminished humoral response and impaired molecular B cell memory formation upon vaccination with BNT162b2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Federal Ministry of Education and Research (BMBF) grant BCOVIT, 01KI20161 (ES). The Berlin Institute of Health with the Charite Clinician Scientist Program funded by the Charite Universitaetsmedizin Berlin and the Berlin Institute of Health (ES) The Berlin Institute of Health with the Starting Grant Multi Omics Characterization of SARS-CoV-2 infection, Project 6 Identifying immunological targets in Covid 19 (MFM). Ministry for Science, Research and Arts of Baden-Wuerttemberg, Germany (HS) German Society of Rheumatology grant (ALS) Sonnenfeldstiftung grant, Berlin, Germany (AS, KK) Deutsche Forschungsgemeinschaft grants KO 2270/7 1, KO-2270/4 1 (KK); Do491/7 5, 10 2, 11 1, Transregio 130 TP24 (TD) State of Berlin and the European Regional Development Fund with the grant ERDF 2014 2020, EFRE 1.8/11, Deutsches Rheuma-Forschungszentrum (MFM) The Deutsche Forschungsgemeinschaft (DFG) through the TRR130 P16 and TRR241 B03 (AR) The Leibniz Association (Leibniz Collaborative Excellence, TargArt) (MFM) COLCIENCIAS scholarship No. 727, 2015 (HRA)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent according to the approval of the ethics committee at the Charite University Hospital Berlin (EA2/010/21, EA4/188/20), the ethics committee of Saxony-Anhalt (EA7/21) and the ethics committee of the University of Greifswald (BB019/21).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the main text or the supplementary materials.
